Randomized phase 2 trial of Intravenous Gamma Globulin (IVIG) for the treatment of acute vaso-occlusive crisis in patients with sickle cell disease: Lessons learned from the midpoint analysis.
Complement Ther Med
; 52: 102481, 2020 Aug.
Article
en En
| MEDLINE
| ID: mdl-32951731
ABSTRACT
Sickle Cell Disease (SCD) is a chronic hemolytic disorder associated with frequent pain episodes, end organ damage and a shortened lifespan. Currently there exist no disease specific targeted therapies for the treatment of acute vaso-occlusive crisis (VOC) and management with analgesics and hydration is purely supportive. Improvement in understanding of disease pathophysiology has resulted in a great interest in disease modifying novel therapies and many are being evaluated in clinical trials. Here we report the results from the pre-specified mid-point analysis of the Phase 2 study of Intravenous Gamma Globulin (IVIG) for the treatment of acute VOC in patients with SCD and lessons learned.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Gammaglobulinas
/
Inmunoglobulinas Intravenosas
/
Manejo del Dolor
/
Anemia de Células Falciformes
Tipo de estudio:
Clinical_trials
Idioma:
En
Revista:
Complement Ther Med
Asunto de la revista:
TERAPIAS COMPLEMENTARES
Año:
2020
Tipo del documento:
Article